BellaSeno is advancing a bioresorbable scaffold platform designed to guide large volume soft tissue formation at scale. Starting with breast applications, this approach supports the body’s own processes to generate, integrate, and adapt tissue over time.
Following positive two-year human clinical data from its scaffold-guided regenerative program, BellaSeno has announced an exclusive global licensing agreement with Mentor Worldwide LLC, a Johnson & Johnson company.
This collaboration will bring together BellaSeno’s technology alongside the clinical, regulatory and commercial scale of one of the world’s leading healthcare companies. As breast aesthetics continues to evolve, there is growing demand for approaches that expand the range of solutions available to patients and surgeons. This collaboration will help accelerate the final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.
Our proprietary PCL scaffold is engineered with interconnected porosity to support vascularization and tissue ingrowth without the need for biologics or stem cells.
A versatile technology platform with expanding potential across breast, chest wall, bone, and other soft tissue applications.
Designed to support tissue integration and regenerative healing as the scaffold gradually resorbs overtime.
Proprietary high-speed Additive Manufacturing method for reproducible quality and scalable manufacturing to meet global clinical demand.
Advancing soft-tissue regeneration for breast revision and primary augmentation.
Our resorbable scaffold platform is being evaluated to support soft-tissue management and regenerative treatment approaches in breast surgery.
Learn More About Breast →A platform with the potential to transform care across multiple indications.
Scaffold-based solutions designed for chest wall reconstruction and pectus correction procedures.
Structural scaffold solutions designed to support bone reconstruction in complex defects.
Applications across soft-tissue reconstruction in a range of anatomical indications.
A differentiated platform with meaningful potential.
Proprietary resorbable scaffold with unique architecture designed to support true tissue regeneration without the need for stem cells or biologics.
Promising clinical experience with long-term follow-up and continued patient outcomes.
Multi-indication potential in large, growing markets across breast and beyond.
Deutscher Platz 5A
04103 Leipzig
Germany
4 Starling Street
Burliegh Heads
QLD, Australia, 4220